Announcement on Obtaining U.S. FDA Clinical Trial Approval for ART002g1 Injection by Controlled Subsidiary
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(600211)"Tibet Rhodiola Pharmaceutical Holding Co., Ltd."Announcement on Obtaining U.S. FDA Clinical Trial Approval for ART002g1 Injection by Controlled Subsidiary
Filed with SSE · Stock code 600211 · · 2 pages · Chinese
Release
Tibet Rhodiola Pharmaceutical Holding Co. on 6ix
Story so far
- (600211)"Tibet Rhodiola Pharmaceutical Holding Co., Ltd."Announcement on Release of Pledge of Certain Shares Held by Shareholder Holding More Than 5% of the Shares
- (600211)"Tibet Rhodiola Pharmaceutical Holding Co., Ltd."Announcement on Progress in Repurchasing Shares
- Announcement on Progress in Providing Guarantee for Controlled Subsidiary
Earlier from Tibet Rhodiola Pharmaceutical
- (600211)"Tibet Rhodiola Pharmaceutical Holding Co., Ltd."Announcement on Release of Pledge of Certain Shares Held by Shareholder Holding More Than 5% of the Shares
- (600211)"Tibet Rhodiola Pharmaceutical Holding Co., Ltd."Announcement on Progress in Repurchasing Shares
- Announcement on Implementation of Dividend Distribution for the First Half of 2026
- Announcement on Outline of the 2026 Semi-annual Performance Briefing
- Announcement on Convening the 2026 Semi-annual Performance Briefing
Follow Tibet Rhodiola Pharmaceutical into a list and get an email when it puts out news.
Follow Tibet Rhodiola Pharmaceutical